High Field Magnetic Resonance Spectroscopy Imaging for Follow Up of Prostate Cancer Post Brachytherapy Implantation

This study has been completed.

First Received on August 3, 2005. Last Updated on March 19, 2012 History of Changes

Sponsor:	Alberta Health Services
Information provided by (Responsible Party):	Alberta Health Services
ClinicalTrials.gov Identifier:	NCT00126854

Purpose

The purpose of this study is to establish the correct scanning parameters for obtaining good quality 3 Tesla (3T) magnetic resonance spectroscopy images (MRSI) of the prostate gland before and after brachytherapy implantation for prostate cancer. Three Tesla MRSI may be a valuable additional diagnostic and follow-up investigation for prostate cancer patients.

Condition	Intervention
Prostatic Neoplasm	Procedure: Magnetic Resonance Spectroscopy Imaging

Study Type:	Interventional
Study Design:	Endpoint Classification: Safety/Efficacy Study Intervention Model: Single Group Assignment Masking: Open Label Primary Purpose: Diagnostic
Official Title:	High Field (3 Tesla) Magnetic Resonance Spectroscopy Imaging for Follow Up of Prostate Cancer Post Permanent Iodine 125 Brachytherapy Implantation

Resource links provided by NLM:

MedlinePlus related topics: Cancer Prostate Cancer

U.S. FDA Resources

Further study details as provided by Alberta Health Services:

Primary Outcome Measures:

pilot study meant to establish scanning parameters on 3T MRSI

Secondary Outcome Measures:

safety/toxicity

Enrollment:	10
Study Start Date:	October 2005
Study Completion Date:	April 2011
Primary Completion Date:	April 2011 (Final data collection date for primary outcome measure)

Eligibility

Ages Eligible for Study:	18 Years and older
Genders Eligible for Study:	Male
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Suitable candidate for prostate brachytherapy to treat prostate cancer
Patient signs a study consent form

Exclusion Criteria:

Have received other radiotherapy for prostate cancer or hormone treatments
Has contraindication to MRSI scanning
Does not sign study consent form

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00126854

Locations

Canada, Alberta
Cross Cancer Institute
Edmonton, Alberta, Canada, T6G 1Z2

Sponsors and Collaborators

Alberta Health Services

Investigators

Principal Investigator:

Don Yee, MD

Alberta Health Services

More Information

No publications provided

Responsible Party:	Alberta Health Services
ClinicalTrials.gov Identifier:	NCT00126854 History of Changes
Other Study ID Numbers:	NA-15-0003 / 22011
Study First Received:	August 3, 2005
Last Updated:	March 19, 2012
Health Authority:	Canada: Health Canada

Keywords provided by Alberta Health Services:

brachytherapy
magnetic resonance spectroscopy

Additional relevant MeSH terms:

Neoplasms
Prostatic Neoplasms
Genital Neoplasms, Male
Urogenital Neoplasms

Neoplasms by Site
Genital Diseases, Male
Prostatic Diseases

ClinicalTrials.gov processed this record on May 21, 2012